Teva Delivers First US Forteo Equivalent
Approved Teriparatide Generic Is Slated To Launch ‘In The Coming Weeks’
Teva has celebrated a US nod for its generic version of Forteo, the first substitutable teriparatide rival to be approved by the US Food and Drug Administration.
You may also be interested in...
Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.
Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.
Teva’s commercial interests in North America will soon be under new leadership after the firm announced that Sven Dethlefs would leave the company in mid-November. The firm has looked to the branded sector for his replacement.